-
1
-
-
0034235179
-
Molecular monitoring of minimal residual disease in patients in long term complete remission after allogeneic stem cell transplantation for multiple myeloma
-
Cavo M, Terragna C, Martinelli G et al. Molecular monitoring of minimal residual disease in patients in long term complete remission after allogeneic stem cell transplantation for multiple myeloma. Blood 2000; 96: 355-357.
-
(2000)
Blood
, vol.96
, pp. 355-357
-
-
Cavo, M.1
Terragna, C.2
Martinelli, G.3
-
2
-
-
0021322023
-
Effective treatment of advanced multiple myeloma resistant to alkylating agents
-
Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma resistant to alkylating agents N Engl J Med 1984; 310: 1353-1356.
-
(1984)
N Engl J Med
, vol.310
, pp. 1353-1356
-
-
Barlogie, B.1
Smith, L.2
Alexanian, R.3
-
3
-
-
0024357763
-
Infusion of viacristine and doxorubicin with oral dexamethasone as first line therapy for multiple myeloma
-
Samson R, Gaqminara E, Newland AC et al. Infusion of viacristine and doxorubicin with oral dexamethasone as first line therapy for multiple myeloma Lancet 1989; 2: 882-885.
-
(1989)
Lancet
, vol.2
, pp. 882-885
-
-
Samson, R.1
Gaqminara, E.2
Newland, A.C.3
-
4
-
-
26844453345
-
Perspectives for combination therapy to overcome drug-resistant multiple myeloma
-
Catley L, Tai Y, Chauhan D, Andersen KC. Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resistance Updates 2005; 8: 205-218.
-
(2005)
Drug Resistance Updates
, vol.8
, pp. 205-218
-
-
Catley, L.1
Tai, Y.2
Chauhan, D.3
Andersen, K.C.4
-
5
-
-
0035200513
-
DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma
-
Lazzarino M, Corso A, Barbarano L et al. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant 2001; 28: 835-839.
-
(2001)
Bone Marrow Transplant
, vol.28
, pp. 835-839
-
-
Lazzarino, M.1
Corso, A.2
Barbarano, L.3
-
6
-
-
0036800307
-
A combination of dexamethasone, cyclophosphamide, etoposide and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma
-
Corso A, Arcaini L, Caberlon S et al. A combination of dexamethasone, cyclophosphamide, etoposide and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. Haematologica 2002; 87: 1041-1045.
-
(2002)
Haematologica
, vol.87
, pp. 1041-1045
-
-
Corso, A.1
Arcaini, L.2
Caberlon, S.3
-
7
-
-
0003247367
-
Dexamethasone, cyclophosphamide, etoposide and cisplatinum (DCEP): An effective regimen for relapse after high-dose chemotherapy and autologous transplantation
-
Munshi NC, Desihan KR, Jagannath S et al. Dexamethasone, cyclophosphamide, etoposide and cisplatinum (DCEP): an effective regimen for relapse after high-dose chemotherapy and autologous transplantation. Blood 1996; 88 (Suppl 1): 586a.
-
(1996)
Blood
, vol.88
, Issue.SUPPL. 1
-
-
Munshi, N.C.1
Desihan, K.R.2
Jagannath, S.3
-
8
-
-
31344455109
-
Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma
-
Gojo I, Meisenberg B, Guo C et al. Autologous stem cell transplantation followed by consolidation chemotherapy for patients with multiple myeloma. Bone Marrow Transplant 2006; 37: 65-72.
-
(2006)
Bone Marrow Transplant
, vol.37
, pp. 65-72
-
-
Gojo, I.1
Meisenberg, B.2
Guo, C.3
-
9
-
-
0035045698
-
High-dose therapy and innovative approaches to treatment of multiple myeloma
-
Barlogie B. High-dose therapy and innovative approaches to treatment of multiple myeloma. Semin Hematol 2001; 38 (2 Suppl 3): 21-27.
-
(2001)
Semin Hematol
, vol.38
, Issue.2 SUPPL. 3
, pp. 21-27
-
-
Barlogie, B.1
-
10
-
-
20444433230
-
Bortezomib or high dose dexamethasone for relapsed multiple myeloma
-
Richardson PG, Sonneveld P, Schuster M et al. Bortezomib or high dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
-
(2005)
N Engl J Med
, vol.352
, pp. 2487-2498
-
-
Richardson, P.G.1
Sonneveld, P.2
Schuster, M.3
-
11
-
-
0032748385
-
Antitumor activity of thalidomide in refractory multiple myeloma
-
Singhal S, Mehta J, Desikan R et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-1571.
-
(1999)
N Engl J Med
, vol.341
, pp. 1565-1571
-
-
Singhal, S.1
Mehta, J.2
Desikan, R.3
-
12
-
-
11144356289
-
Pulsed cyclophosphamide, thalidomide and dexamethasone; an oral regimen for previously treated patients with multiple myeloma
-
Dimopoulos MA, Hamilos G, Zomas A et al. Pulsed cyclophosphamide, thalidomide and dexamethasone; an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004; 5: 112-117.
-
(2004)
Hematol J
, vol.5
, pp. 112-117
-
-
Dimopoulos, M.A.1
Hamilos, G.2
Zomas, A.3
-
13
-
-
0037973279
-
A phase 2 study of bortezomib in relapsed, refractory myeloma
-
Richardson PG, Barlogie B, Berenson J et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
-
(2003)
N Engl J Med
, vol.348
, pp. 2609-2617
-
-
Richardson, P.G.1
Barlogie, B.2
Berenson, J.3
-
14
-
-
33745801771
-
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone
-
Jagannath S, Richardson PG, Barlogie B et al. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006; 91: 929-934.
-
(2006)
Haematologica
, vol.91
, pp. 929-934
-
-
Jagannath, S.1
Richardson, P.G.2
Barlogie, B.3
-
15
-
-
30844443713
-
Low dose velcade, thalidomide and dexamethasone (LD-VTD): An effective regimen for relapsed and refractory multiple myeloma
-
Cioli S, Leoni F, Gigli F, Rigac L, Bosi A. Low dose velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma. Leuk Lymphoma 2006; 47: 171-173.
-
(2006)
Leuk Lymphoma
, vol.47
, pp. 171-173
-
-
Cioli, S.1
Leoni, F.2
Gigli, F.3
Rigac, L.4
Bosi, A.5
-
16
-
-
33644916110
-
Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
-
Berenson JR, Yang HH, Sadler K et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006; 24: 937-944.
-
(2006)
J Clin Oncol
, vol.24
, pp. 937-944
-
-
Berenson, J.R.1
Yang, H.H.2
Sadler, K.3
-
17
-
-
0036839013
-
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma
-
Richardson PG, Schlossman RL, Weller E et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002; 100: 3063-3067.
-
(2002)
Blood
, vol.100
, pp. 3063-3067
-
-
Richardson, P.G.1
Schlossman, R.L.2
Weller, E.3
-
18
-
-
0034331194
-
Thalidomide and its analogs overcome drug resistance of multiple myeloma cells to conventional therapy
-
Hideshima T, Chauhan D, Shima Y et al. Thalidomide and its analogs overcome drug resistance of multiple myeloma cells to conventional therapy. Blood 2000; 96: 2943-2950.
-
(2000)
Blood
, vol.96
, pp. 2943-2950
-
-
Hideshima, T.1
Chauhan, D.2
Shima, Y.3
-
19
-
-
33750607347
-
A randomized phase 2 study of lenalidomide therapy for patients with relapsed and refractory multiple myeloma
-
Richardson PG, Blood E, Mitsiades CS et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed and refractory multiple myeloma. Blood 2006; 108: 3458-3464.
-
(2006)
Blood
, vol.108
, pp. 3458-3464
-
-
Richardson, P.G.1
Blood, E.2
Mitsiades, C.S.3
|